{"id":178860,"date":"2025-08-21T06:17:19","date_gmt":"2025-08-21T05:17:19","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/"},"modified":"2025-08-21T06:17:19","modified_gmt":"2025-08-21T05:17:19","slug":"evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/","title":{"rendered":"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado"},"content":{"rendered":"<p>El Servicio de Oncolog\u00eda del\u00a0<a href=\"http:\/\/www.ibsalut.es\/asef\/es\/\" rel=\"noopener\">Hospital Can Misses<\/a> ha participado en la publicaci\u00f3n de los resultados finales del estudio CADIM sobre la evidencia en la pr\u00e1ctica cl\u00ednica del tratamiento adyuvante con inmunoterapia en pacientes con melanoma en estadios III y IV secados.<\/p>","protected":false},"excerpt":{"rendered":"<p>El Servicio de Oncolog\u00eda del\u00a0Hospital Can Misses ha participado en la publicaci\u00f3n de los resultados finales del estudio CADIM sobre la evidencia en la pr\u00e1ctica cl\u00ednica del tratamiento adyuvante con inmunoterapia en pacientes con melanoma en estadios III y IV secados.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-178860","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.9 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado\" \/>\n<meta property=\"og:description\" content=\"El Servicio de Oncolog\u00eda del\u00a0Hospital Can Misses ha participado en la publicaci\u00f3n de los resultados finales del estudio CADIM sobre la evidencia en la pr\u00e1ctica cl\u00ednica del tratamiento adyuvante con inmunoterapia en pacientes con melanoma en estadios III y IV secados.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T05:17:19+00:00\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado\",\"datePublished\":\"2025-08-21T05:17:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/\"},\"wordCount\":57,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/\",\"name\":\"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"datePublished\":\"2025-08-21T05:17:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/","og_locale":"es_ES","og_type":"article","og_title":"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado","og_description":"El Servicio de Oncolog\u00eda del\u00a0Hospital Can Misses ha participado en la publicaci\u00f3n de los resultados finales del estudio CADIM sobre la evidencia en la pr\u00e1ctica cl\u00ednica del tratamiento adyuvante con inmunoterapia en pacientes con melanoma en estadios III y IV secados.","og_url":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/","og_site_name":"bip4ex","article_published_time":"2025-08-21T05:17:19+00:00","author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado","datePublished":"2025-08-21T05:17:19+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/"},"wordCount":57,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/","url":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/","name":"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"datePublished":"2025-08-21T05:17:19+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/evidencia-clinica-de-la-inmunoterapia-adyuvante-en-melanoma-iii-iv-secado\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Evidencia cl\u00ednica de la inmunoterapia adyuvante en melanoma III-IV secado"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/178860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=178860"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/178860\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=178860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=178860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=178860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}